

## ASX ANNOUNCEMENT MARKET RELEASE

12 February 2025

### Artrya secures multi-year commercial contract with Sonic Healthcare Australia

#### Highlights

- **Artrya secures commercial contract with Sonic Healthcare Australia - Radiology for use of Salix® Coronary Anatomy platform for coronary artery disease assessment at the point of care**
- **The three-year contract will generate revenue through a Software-as-a-Service (SaaS) subscription model, with initial revenue anticipated in Q4 FY25.**
- **Sonic Healthcare is the second largest diagnostic imaging provider in Australia, with more than 125 radiology centres, and the first large radiology group in Australia to leverage Salix to assist in the diagnosis of coronary artery disease.**

Artrya Limited (ASX:AYA), ('Artrya' or the 'Company'), a medical technology company focused on commercialising its patented artificial intelligence platform that detects key coronary artery disease imaging markers, has secured a three-year commercial agreement with Sonic Healthcare Australia - Radiology (Sonic) for the use of Salix® Coronary Anatomy platform (Salix).

The contract will generate revenue through a Software-as-a-Service (SaaS) subscription model, with initial revenue anticipated in Q4 FY25.

Sonic Healthcare is a globally recognised healthcare provider operating across Australasia, North America and Europe. As the second-largest radiology diagnostic imaging group in Australia, Sonic manages over 125 radiology<sup>1</sup> centres and boasts a network of 1,800 radiologists and pathologists, supported by more than 17,000 medical scientists, radiographers, sonographers, technicians, and nurses.

Under the agreement, Salix will be integrated into all Sonic Healthcare Radiology centres that perform Coronary Computed Tomography Angiography (CCTA) scans for coronary heart disease detection. Salix is designed to enhance accuracy and efficiency in detecting stenoses and other critical markers, including high-risk plaque from CCTA scans, whilst also optimizing clinical workflow.

#### Artrya CEO Mathew Regan said:

*"Our contract with Sonic is a significant milestone for our commercial growth in Australia. We are thrilled to partner with a globally leading healthcare provider who is also Australia's second largest radiology group, placing our lifesaving, AI-driven technology in the hands of Australian clinicians to improve the diagnosis of the world's number one killer, heart disease."*

<sup>1</sup> <https://www.sonicradiology.com.au/about/>

*“Sonic has a significant presence throughout Australia with over 125 radiology clinics, many of which perform CCTA scans for heart disease detection and diagnosis.”*

**Sonic Healthcare Australia - Radiology CEO Dr Julian Adler said:**

*“We are proud to incorporate Salix as part of our first line process for cardiovascular care. Salix offers an evidence-based, personalised approach to the imaging of patients at risk for coronary vascular disease. Importantly, Salix provides a rapid, full assessment of the coronary arteries at the point of care, thus supporting our skilled cardiovascular imaging specialists and significantly improving the diagnostic workflow for our patients and their referrers. Artrya’s technology enhances the standard of care for the non-invasive diagnosis of coronary artery disease.”*

**Material terms of the agreement**

Material terms of the agreement are defined and listed in the attached Appendix 1.

This announcement was approved by the Board.

**For further information please contact:**

**Investor**

Danny Younis

+61 420 293 042

[danny.younis@automicgroup.com.au](mailto:danny.younis@automicgroup.com.au)

**Media**

Rama Razy

+61 498 440 142

[rama.razy@automicgroup.com.au](mailto:rama.razy@automicgroup.com.au)

**About Artrya**

Based in Perth, Australia, Artrya was founded in 2018 with operations starting in early 2019. The Company was listed on the Australian Securities Exchange (ASX: AYA) in 2021.

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of at-risk patients. The company has developed deep-learning algorithms pending regulatory submission for clearance and approval in the US that will serve to predict and prevent acute coronary events.

For more information, see [www.artrya.com](http://www.artrya.com)

**About Sonic Healthcare Ltd**

Sonic Healthcare is an internationally renowned healthcare provider with specialist operations in laboratory medicine / pathology, radiology, general practice medicine and corporate medical services. Headquartered in Sydney, Australia, Sonic has grown to become one of the world’s leading healthcare providers, with operations in Australasia, Europe and North America.

Across our organisation, our diagnostic and clinical services are provided by 1,800 pathologists and radiologists, and more than 17,000 medical scientists, radiographers, sonographers, technicians and nurses, all of whom are led by highly experienced medical personnel, from Board level through to the management of our local practices.

Artrya Limited  
ACN 624 005 741  
1257 Hay Street West Perth WA 6005  
PO Box 567 West Perth WA 6872  
[www.artrya.com](http://www.artrya.com)  
T: +61 8 6478 7816

## Appendix 1

### Key Terms

Licensee	Sonic Healthcare Australia - Radiology
Contract type	SAAS Software Licence Agreement
Product	The Software as a Medical Device known as Salix® Coronary Anatomy
Territory	Australia
Contract term	36-month subscription Termination 30 days with written notice
Revenue Impact	<i>The contract will generate revenue through a Software-as-a-Service (SaaS) subscription model. The revenue impact of this agreement is not considered material in value as it is dependent on future scan numbers and rates of take-up. Artrya is using the Australian market as an excellent environment to test our software and obtain valuable clinical information in preference to generating material revenue from the Australian market.</i>
Special terms	Artrya will commence invoicing the Licensee upon completion of integration into Licensee's imaging and reporting systems and satisfactory completion of user acceptance testing.